Replies to post #814420 on NorthWest Biotherapeutics Inc (NWBO)

[sukus]

Imagine if DCvax was approved in 2024 folks? This fast lane is not ready. It will be a nightmare? I think so. DCvax is approved in 2026 is a much better choice. UK has worked especially hard. I found it amazing. Amazing is maybe a lack of better words.
The "Poster Child" Proof: NWBO (ID836) has been on the NICE radar since 2018. It was "rescheduled to align with latest regulatory expectations." This is the administrative code for: "We moved this drug out of the slow lane and into the Aligned Pathway Exemplar lane."

[sukus]

I highlighted into nuggets folks. Easier to digest those most important.
Why "Poster Child" is the correct term:If you look at the Southampton Clinical Trials Unit (which runs the CVLP on behalf of the NHS), they stated on Feb 4th that this exemplar study is about "accelerating patient access to trials of new cancer vaccines and novel immunotherapy treatments."• BioNTech is the "Partner for mRNA."• NWBO is the "Logic for Cell-Based Immunotherapy."The UK government needs a win to show their £2.3 billion investment is working. They have the factory (Sawston), the funding (LSIMF), and the patients (CVLP). The only thing missing is the NICE "Yes" 

[Chiugray]

Sukus, I see why you are highlighting the NHS Cancer Vaccine Launch Pad (CVLP) program. The benefits are major (accelerates time and saves costs in trials). Adding some AI research and thoughts to yours. I believe the big opportunity is for DCVax-Direct. IMO this will enable NWBO to run a large Phase 2/3 adaptive design pivotal clinical trial.

CVLP
Summary
- Sponsor: NHS England (primary sponsor for CVLP platform)
- Operational Manager: Southampton Clinical Trials Unit (SCTU). They are the central hub that manages data, tracks biological samples, and matches patients to clinical trial
- The Data: SCTU holds the central database of pseudonymized patient data.
- Provide “up to 10,000 patients with personalised cancer treatments in the UK by 2030.”
- Detection: a low-cost liquid biopsy (blood test) flags cancer DNA
- Analysis: lab does whole genome sequencing (WGS)
- CVLP engine then selects the best vaccine trial (ie DCVax vs mRNA, other) based on patient’s stage and mutation profile.

NHS’ landscape of hospitals becomes a high-speed search engine and middleman that handles the most expensive and time-consuming parts of a clinical trial:
- Site selection: Done, 140+ NHS sites already “vaccine-ready” and linked
- Referring sites: NHS hospitals in England. They find the patients, get consent, blood test, and conduct WGS
- Trial sites: Patient is then sent to the hospital running the trial
- Patient recruitment: Automated. CVLP screens patient using WGS and matches them to trials
- Staffing: NHS provides clinical teams and “Associate Principal Investigators” (a junior doctor/nurse who officially runs the trial’s daily activities, ie training to be a PI)
- Data management: Centralized, SCTU manages the data flow, tracking, and sharing

- (key) Don’t have to convince 100 hospitals to run your trial, just a few “hub” hospitals. The CVLP finds patients and will funnel them there.)
- (key) Time to enrollment: Accelerated significantly
- (key) Costs: Some sharing, but much savings

NWBO Opportunity, a CVLP enabled pivotal trial design (hypothetically)
- DCVax-Direct Phase 2/3 adaptive design, pivotal, with a basket trial with 4-6 cancer types
- Likely targets from Phase 1: pancreatic, colorectal, melanoma, liver, sarcoma, lung
- Stage 1 (Phase 2 part): 150 patients in months 1-12
- Stage 2 (Phase 3 expansion part, if Stage 1 is positive): 300 patients in months 12-24
- Total 450 patients
- Primary endpoint: ORR or OS vs historical controls
- Interim analysis: at 18 months

WHY DCVax-Direct should fit CVLP better than mRNA and DCVax-L
- No surgery required: Direct uses image-guided injection (saves time, cost, and expands eligible patient population to include inoperable tumors)
- Time to first dose: Direct is 1-2 weeks (~7 days Flaskworks manufacturing) vs mRNA vaccines at 8-18 weeks (surgery + recovery + post-radiation buffer + manufacturing). Direct can be administered during chemo/radiation as concurrent therapy, maximizing synergy
- Economics: Direct with Flaskworks' low-cost automated manufacturing provides significant cost savings vs mRNA's custom sequencing/synthesis. Add elimination of surgery costs, and savings increase further. mRNA vaccines typically require pairing with checkpoint inhibitors (like Keytruda).